Cingulate (CING) Stock Price, News & Analysis

Company Overview

Cingulate Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s lead programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to provide controlled, timed releases of medication from a single oral dose.

Cingulate’s primary product candidate is CTx-1301, an extended-release formulation of dexmethylphenidate intended to provide all-day ADHD symptom control through multiple releases of the active ingredient. The company has also worked on additional investigational candidates, including CTx-1302, as it seeks to apply its delivery technology to other potential treatments.

Founded in 2012 and headquartered in Kansas City, Kansas, Cingulate has focused its clinical development activities primarily on the U.S. market. The company has no broadly marketed commercial product and continues to depend on clinical development and regulatory review for its candidates. Shane Schaffer, the company’s founder, has served as its chief executive officer.

Key Stats

• Today's Range: $4.18 to $4.60
• 50-Day Range: $4.24 to $5.53
• 52-Week Range: $3.16 to $11.89
• Volume: 66,581 shs
• Average Volume: 356,077 shs
• Market Capitalization: $61.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Moderate Buy

Cingulate Stock Analysis - MarketRank™

Cingulate scored higher than 38% of companies evaluated by MarketBeat, and ranked 702nd out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Cingulate has a consensus price target of $27.00, representing about 496.7% upside from its current price of $4.53.

Amount of Analyst Coverage

Cingulate has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cingulate are expected to grow in the coming year, from ($2.19) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cingulate is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cingulate is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cingulate has a P/B Ratio of 14.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.53% of the float of Cingulate has been sold short.

Short Interest Ratio / Days to Cover

Cingulate has a short interest ratio ("days to cover") of 7.52.

Change versus previous month

Short interest in Cingulate has recently increased by 2.03%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cingulate does not currently pay a dividend.

Dividend Growth

Cingulate does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.61

News Sentiment

Cingulate has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cingulate this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cingulate insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.30% of the stock of Cingulate is held by insiders.

Percentage Held by Institutions

41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CING
• CIK: 1862150
• Web: www.cingulate.com
• Phone: 913-942-2300
• Fax: N/A
• Employees: 14
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Cingulate: $27.00
• High Price Target: $52.00
• Low Price Target: $9.00
• Potential Upside/Downside: +534.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -238.40%
• Return on Assets: -128.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 3.50

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 13.73

Miscellaneous

• Outstanding Shares: 14,540,000
• Free Float: 13,771,000
• Market Cap: $61.87 million
• Optionable: Optionable
• Beta: -0.88